[{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Emerson Urology Associates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Mycobacterium Bovis Bacille Calmette-guerin Vaccine","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ludwig Enterprises","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ludwig Enterprises \/ Emerson Urology Associates","highestDevelopmentStatusID":"1","companyTruncated":"Ludwig Enterprises \/ Emerson Urology Associates"},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Amino Acid Mixture","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Ludwig Enterprises","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Ludwig Enterprises \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ludwig Enterprises \/ Not Applicable"},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Ludwig Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Temozolomide","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ludwig Enterprises","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ludwig Enterprises \/ Ludwig Enterprises","highestDevelopmentStatusID":"4","companyTruncated":"Ludwig Enterprises \/ Ludwig Enterprises"}]

Find Clinical Drug Pipeline Developments & Deals by Ludwig Enterprises

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The net proceeds will be used to fund a preclinical study on Glioblastoma (GBM), an incurable brain cancer, to potentially increase the efficacy of Merck's FDA approved drug Temodar (temozolomide).

                          Brand Name : Temodar

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 27, 2024

                          Lead Product(s) : Temozolomide

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : University of Central florida

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : NuGenea is a nutraceutical formulated with 20 different ingredients which have been scientifically shown to help fight chronic inflammation, which is a causative factor in illnesses such as cancer, diabetes, COPD and heart disease.

                          Brand Name : NuGenea

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 25, 2023

                          Lead Product(s) : Amino Acids Mixture

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Lead Product(s) : Mycobacterium Bovis Bacille Calmette-guerin Vaccine

                          Therapeutic Area : Oncology

                          Study Phase : Undisclosed

                          Sponsor : Emerson Urology Associates

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Bacillus Calmette-Guérin (BCG) is a cancer vaccine that uses weakened bacteria to stimulate the immune system. BCG (mycobacterium bovis bacille calmette-guerin vaccine) has received U.S. FDA approval for the treatment of early-stage bladder cancer.

                          Brand Name : BCG

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 20, 2022

                          Lead Product(s) : Mycobacterium Bovis Bacille Calmette-guerin Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Emerson Urology Associates

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank